Eli Lilly And Co (LLY) Receives $117.32 Average Target Price from Brokerages

Shares of Eli Lilly And Co (NYSE:LLY) have earned a consensus rating of “Buy” from the twenty-three research firms that are presently covering the firm, MarketBeat Ratings reports. Ten analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $118.83.

LLY has been the subject of a number of recent research reports. UBS Group decreased their price objective on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a report on Friday, February 8th. Barclays reissued a “buy” rating and set a $140.00 price objective on shares of Eli Lilly And Co in a report on Sunday, April 14th. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a report on Monday, February 4th. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price objective for the company in a report on Wednesday, April 10th. Finally, Edward Jones raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a report on Tuesday, April 23rd.

In other news, SVP Enrique A. Conterno sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $121.00, for a total value of $3,025,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total value of $25,108,400.00. Following the completion of the transaction, the insider now owns 117,641,684 shares in the company, valued at approximately $14,408,753,456.32. The disclosure for this sale can be found here. Insiders sold a total of 863,382 shares of company stock worth $108,785,182 in the last 90 days. Company insiders own 0.11% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. Trust Department MB Financial Bank N A lifted its stake in Eli Lilly And Co by 54.7% in the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares during the last quarter. Captrust Financial Advisors lifted its stake in Eli Lilly And Co by 0.4% in the fourth quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock valued at $2,503,000 after purchasing an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. lifted its stake in Eli Lilly And Co by 1.6% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock valued at $641,000 after purchasing an additional 87 shares during the last quarter. First Personal Financial Services lifted its stake in Eli Lilly And Co by 2.3% in the fourth quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock valued at $455,000 after purchasing an additional 89 shares during the last quarter. Finally, Carroll Financial Associates Inc. lifted its stake in Eli Lilly And Co by 1.3% in the fourth quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock valued at $810,000 after purchasing an additional 91 shares during the last quarter. Hedge funds and other institutional investors own 79.36% of the company’s stock.

Shares of Eli Lilly And Co stock opened at $118.46 on Friday. Eli Lilly And Co has a one year low of $77.09 and a one year high of $132.13. The stock has a market capitalization of $121.23 billion, a P/E ratio of 21.34, a PEG ratio of 2.22 and a beta of 0.27. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 45.44% and a net margin of 26.13%. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. During the same period in the previous year, the company posted $1.31 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Analysts expect that Eli Lilly And Co will post 5.67 EPS for the current fiscal year.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: What is the price-to-earnings growth (PEG) ratio?

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.